Molecular targeted therapy for the treatment of gastrointestinal stromal tumor
10.3760/cma.j.issn.1673-9752.2013.04.004
- VernacularTitle:胃肠道间质瘤的分子靶向治疗
- Author:
Jian LI
- Publication Type:Journal Article
- Keywords:
Gastrointestinal stomal tumor;
Molecular targeted therapy;
Gene mutation
- From:Chinese Journal of Digestive Surgery
2013;(4):253-256
- CountryChina
- Language:Chinese
-
Abstract:
Molecular targeted agents changed the therapeutic pattern on gastrointestinal stromal tumor (GIST).Imatinib of 400 mg/d is recommended to be the first line therapy for metastatic GIST.Escalation of imatinib dose or sunitinib could improve the overall survival of patients when the treatment with standard dose of imatinib failed.In addition,new targeted agents showed potential anti-tumor efficacy.Imatinib adjuvant therapy could improve the recurrence-free survival of GIST patients with median or high risk after complete tumor resection.Preoperative treatment with imatinib raises tumor resection rate,but whether it could provide survival benefit has not been proved.C-kit/PDGFRα gene mutation can predict the efficacy of imatinib and sunitinib,and it is helpful to screen out the GIST patients to receive imatinib adjuvant therapy.
